Pharmaceutical Business review

Omnicell Q3 revenues increase

Omnicell has posted a net income of $1.28m for the third quarter 2010, or $0.04 per diluted share, compared to $854,000m, or $0.03 per diluted share, for the comparable period in 2009.

For the nine months ended 30 September 2010, Omnicell has posted revenue of $165.14m, compared to $158.8m for the year ago period.

For the nine months ended 30 September 2010, Omnicell has posted a net income of $4.22m, or $0.13 per diluted share, compared to net loss of $112,000, or $0 loss per diluted share, for the year ago period.

Omnicell president, CEO and chairman Randall Lipps said that Omnicell enjoyed success in the marketplace during the third quarter with orders across their customer base.